Peringatan Keamanan

Some of the most commonly reported adverse effects of triptorelin are hot flushes reported in 58.6% of patients, skeletal pain in 12.1%, impotence in 7.1%, and headache in 5.0%. Other reported adverse effects include injection site pain, general body pain, leg pain, fatigue, hypertension, dizziness, diarrhea, vomiting, insomnia, emotional lability, anemia, pruritus, urinary tract infections, and urinary retention. Triptorelin is classified as Pregnancy Category X and contraindicated in pregnant women or in women who may become pregnant. Hormonal changes caused by triptorelin increase the risk for pregnancy loss. Studies done on pregnant rats demonstrated maternal toxicity and embryo-fetal toxicities.

Triptorelin

DB06825

small molecule approved vet_approved

Deskripsi

Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Struktur Molekul 2D

Berat 1311.473
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The pharmacokinetics of triptorelin follows a 3 compartment model. The half lives are estimated to be 6 minutes, 45 minutes, and 3 hours respectively.
Volume Distribusi After a single IV dose of 0.5mg, the volume of distribution of triptorelin peptide in healthy males was 30 - 33L.
Klirens (Clearance) In healthy male volunteers, total clearance of triptorelin was 211.9 mL/min.

Absorpsi

Following IV administration of triptorelin, triptorelin is completely absorbed.

Metabolisme

The metabolism of triptorelin in humans is not well understood; however, metabolism likely does not involve hepatic enzymes such as cytochrome P450. Whether or not triptorelin affects, or how it affects other metabolizing enzymes is also poorly understood. Triptorelin has no identified metabolites.

Rute Eliminasi

Elimination of triptorelin involves both the kidneys and the liver.

Interaksi Obat

494 Data
Corifollitropin alfa The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Triptorelin.
Choline C 11 Triptorelin may decrease effectiveness of Choline C 11 as a diagnostic agent.
Capromab pendetide Triptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Triptorelin.
Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Triptorelin.
Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Triptorelin.
Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Triptorelin.
Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Triptorelin.
Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Triptorelin.
Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Triptorelin.
Sulfadiazine The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Triptorelin.
Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Triptorelin.
Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Triptorelin.
Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Triptorelin.
Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triptorelin.
Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Triptorelin.
Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Triptorelin.
Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Triptorelin.
Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Triptorelin.
Sulfamethoxazole The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Triptorelin.
Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Triptorelin.
Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Triptorelin.
Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Triptorelin.
Tolbutamide The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triptorelin.
Pioglitazone The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triptorelin.
Bromocriptine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Triptorelin.
Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Triptorelin.
Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Triptorelin.
Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Triptorelin.
Sunitinib The therapeutic efficacy of Sunitinib can be decreased when used in combination with Triptorelin.
Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Triptorelin.
Mecasermin The therapeutic efficacy of Mecasermin can be decreased when used in combination with Triptorelin.
Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Triptorelin.
Glisoxepide The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Triptorelin.
Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Triptorelin.
Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Triptorelin.
Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Triptorelin.
Glymidine The therapeutic efficacy of Glymidine can be decreased when used in combination with Triptorelin.
AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Triptorelin.
Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Triptorelin.
Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Triptorelin.
Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Triptorelin.
NN344 The therapeutic efficacy of NN344 can be decreased when used in combination with Triptorelin.
AMG-222 The therapeutic efficacy of AMG-222 can be decreased when used in combination with Triptorelin.
Bisegliptin The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Triptorelin.
Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Triptorelin.
Dapagliflozin The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Triptorelin.
Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Triptorelin.
Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Triptorelin.
Gosogliptin The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Triptorelin.
Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triptorelin.
Canagliflozin The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.
Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Triptorelin.
Benfluorex The therapeutic efficacy of Benfluorex can be decreased when used in combination with Triptorelin.
Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.
Albiglutide The therapeutic efficacy of Albiglutide can be decreased when used in combination with Triptorelin.
Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Triptorelin.
Lobeglitazone The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Triptorelin.
Netoglitazone The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Triptorelin.
Rivoglitazone The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Triptorelin.
Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Triptorelin.
Lixisenatide The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Triptorelin.
Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Triptorelin.
Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Triptorelin.
Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Triptorelin.
Insulin tregopil The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Triptorelin.
Ipragliflozin The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Triptorelin.
Dutogliptin The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Triptorelin.
Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Triptorelin.
Tofogliflozin The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Triptorelin.
Ertugliflozin The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Triptorelin.
2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Triptorelin.
Teneligliptin The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Triptorelin.
Omarigliptin The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Triptorelin.
Carmegliptin The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Triptorelin.
Gemigliptin The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Triptorelin.
Anagliptin The therapeutic efficacy of Anagliptin can be decreased when used in combination with Triptorelin.
Evogliptin The therapeutic efficacy of Evogliptin can be decreased when used in combination with Triptorelin.
Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Triptorelin.
Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Triptorelin.
Remogliflozin etabonate The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Triptorelin.
Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Triptorelin.
Guar gum The therapeutic efficacy of Guar gum can be decreased when used in combination with Triptorelin.
Metahexamide The therapeutic efficacy of Metahexamide can be decreased when used in combination with Triptorelin.
Semaglutide The therapeutic efficacy of Semaglutide can be decreased when used in combination with Triptorelin.
Taspoglutide The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Triptorelin.
Englitazone The therapeutic efficacy of Englitazone can be decreased when used in combination with Triptorelin.
Tirzepatide The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Triptorelin.
Gastric inhibitory polypeptide The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Triptorelin.
Leuprolide The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Leuprolide.
Goserelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Goserelin.
Erythromycin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Erythromycin.
Azithromycin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Azithromycin.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Moxifloxacin.
Ranolazine The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Ranolazine.
Sulfisoxazole The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Triptorelin.
Amitriptyline The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Amitriptyline.
Methadone The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Methadone.
Diltiazem The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Diltiazem.
Clozapine The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Clozapine.

Target Protein

Gonadotropin-releasing hormone receptor GNRHR

Referensi & Sumber

Artikel (PubMed)
  • PMID: 10969915
    Lahlou N, Carel JC, Chaussain JL, Roger M: Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:723-37.
  • PMID: 15955640
    Padula AM: GnRH analogues--agonists and antagonists. Anim Reprod Sci. 2005 Aug;88(1-2):115-26.

Contoh Produk & Brand

Produk: 17 • International brands: 3
Produk
  • Decapeptyl
    Solution • 0.1 mg / mL • Subcutaneous • Canada • Approved
  • Trelstar
    Injection, powder, for suspension, extended release • 22.5 mg / vial • Intramuscular • Canada • Approved
  • Trelstar
    Injection, powder, lyophilized, for suspension • 11.25 mg/2mL • Intramuscular • US • Approved
  • Trelstar
    Injection, powder, lyophilized, for suspension; Kit • 3.75 mg/2mL • Intramuscular • US • Approved
  • Trelstar
    Injection, powder, lyophilized, for suspension; Kit • 11.25 mg/2mL • Intramuscular • US • Approved
  • Trelstar
    Injection, powder, lyophilized, for suspension; Kit • 22.5 mg/2mL • Intramuscular • US • Approved
  • Trelstar
    Injection, powder, for suspension, extended release • 3.75 mg / vial • Intramuscular • Canada • Approved
  • Trelstar
    Injection, powder, lyophilized, for suspension; Kit • 3.75 mg/2mL • Intramuscular • US • Approved
Menampilkan 8 dari 17 produk.
International Brands
  • Diphereline — Ferring Pharmaceuticals
  • Gonapeptyl — Ferring Pharmaceuticals
  • Variopeptyl — Varian Darou Pajooh

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul